[1] Mandel-Brehm C, Dubey D, Kryzer TJ, O'Donovan BD, Tran B, Vazquez SE, Sample HA, Zorn KC, Khan LM, Bledsoe IO, McKeon A, Pleasure SJ, Lennon VA, DeRisi JL, Wilson MR, Pittock SJ. Kelch-like protein 11 antibodies in seminoma-associated paraneoplastic encephalitis[J]. N Engl J Med, 2019, 381:47-54.
[2] Garcia-Santibanez R, Zaidman CM, Sommerville RB, Lopate G, Weihl CC, Pestronk A, Bucelli RC. CANOMAD and other chronic ataxic neuropathies with disialosyl antibodies (CANDA)[J]. J Neurol, 2018, 265:1402-1409.
[3] Bunschoten C, Jacobs BC, van den Bergh PY, Cornblath DR, van Doorn PA. Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy[J]. Lancet Neurol, 2019, 18:784-794.
[4] Lubetzki C, Zalc B, Williams A, Stadelmann C, Stankoff B. Remyelination in multiple sclerosis:from basic science to clinical translation[J]. Lancet Neurol, 2020, 19:678-688.
[5] Lamb YN. Ozanimod:first approval[J]. Drugs, 2020, 80:841-848.
[6] Zhang C, Zhang M, Qiu W, Ma H, Zhang X, Zhu Z, Yang CS, Jia D, Zhang TX, Yuan M, Feng Y, Yang L, Lu W, Yu C, Bennett JL, Shi FD; TANGO Study Investigators. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO):an open-label, multicentre, randomised, phase 2 trial[J]. Lancet Neurol, 2020, 19:391-401.
[7] Menon D, Barnett C, Bril V. Novel treatments in myasthenia gravis[J]. Front Neurol, 2020, 11:538.
[8] Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ. Chimeric antigen receptor T-cell therapy-assessment and management of toxicities[J]. Nat Rev Clin Oncol, 2018, 15:47-62.
[9] Kao JC, Liao B, Markovic SN, Klein CJ, Naddaf E, Staff NP, Liewluck T, Hammack JE, Sandroni P, Finnes H, Mauermann ML. Neurological complications associated with anti-programmed death 1(PD-1) antibodies[J]. JAMA Neurol, 2017, 74:1216-1222.
[10] Mancinelli CR, Scarpazza C, Cordioli C, De Rossi N, Rasia S, Turrini MV, Capra R. Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab[J]. Mult Scler, 2020, 4:ID1352458520946017.
[11] Jurek B, Chayka M, Kreye J, Lang K, Kraus L, Fidzinski P, Kornau HC, Dao LM, Wenke NK, Long M, Rivalan M, Winter Y, Leubner J, Herken J, Mayer S, Mueller S, Boehm-Sturm P, Dirnagl U, Schmitz D, Kölch M, Prüss H. Human gestational N-methyl-D-aspartate receptor autoantibodies impair neonatal murine brain function[J]. Ann Neurol, 2019, 86:656-670.
[12] Chen S, Zhou QM, Ni Y, Liu J. Yesterday, today and tomorrow of autoimmune encephalitis[J]. Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi, 2020, 20:4-8.[陈晟, 周勤明, 倪优, 刘军. 自身免疫性脑炎的昨天、今天与明天. 中国现代神经疾病杂志, 2020, 20:4-8.]
[13] Wagnon I, Hélie P, Bardou I, Regnauld C, Lesec L, Leprince J, Naveau M, Delaunay B, Toutirais O, Lemauff B, Etard O, Vivien D, Agin V, Macrez R, Maubert E, Docagne F. Autoimmune encephalitis mediated by B-cell response against N-methyl-D-aspartate receptor[J]. Brain, 2020, 7:awaa250.
[14] Peer M, Prüss H, Ben-Dayan I, Paul F, Arzy S, Finke C. Functional connectivity of large-scale brain networks in patients with anti-NMDA receptor encephalitis:an observational study[J]. Lancet Psychiatry, 2017, 4:768-774.
[15] Phillips OR, Joshi SH, Narr KL, Shattuck DW, Singh M, Di Paola M, Ploner CJ, Prüss H, Paul F, Finke C. Superficial white matter damage in anti-NMDA receptor encephalitis[J]. J Neurol Neurosurg Psychiatry, 2018, 89:518-525.